Murine and humanized anti human VEGF antibodies and uses are disclosed. The anti human VEGF antibodies of the invention have higher binding affinity for human VEGF A are stronger inhibitors of the VEGF A induced proliferation of endothelial cells in culture as compared with anti human VEGF antibodies in the art. Moreover these antibodies cross react with human VEGF B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab (AvastinTM) when administered at the same dosage
